634 related articles for article (PubMed ID: 25838343)
1. Pathogenesis beyond the cancer clone(s) in multiple myeloma.
Bianchi G; Munshi NC
Blood; 2015 May; 125(20):3049-58. PubMed ID: 25838343
[TBL] [Abstract][Full Text] [Related]
2. Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back.
Bianchi G; Anderson KC
CA Cancer J Clin; 2014; 64(6):422-44. PubMed ID: 25266555
[TBL] [Abstract][Full Text] [Related]
3. Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
Ho M; Patel A; Goh CY; Moscvin M; Zhang L; Bianchi G
Leukemia; 2020 Dec; 34(12):3111-3125. PubMed ID: 33046818
[TBL] [Abstract][Full Text] [Related]
4. From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells.
van Nieuwenhuijzen N; Spaan I; Raymakers R; Peperzak V
Cancer Res; 2018 May; 78(10):2449-2456. PubMed ID: 29703720
[TBL] [Abstract][Full Text] [Related]
5. Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma.
Bianchi G; Ghobrial IM
Curr Cancer Ther Rev; 2014; 10(2):70-79. PubMed ID: 25705146
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Cesana C; Klersy C; Barbarano L; Nosari AM; Crugnola M; Pungolino E; Gargantini L; Granata S; Valentini M; Morra E
J Clin Oncol; 2002 Mar; 20(6):1625-34. PubMed ID: 11896113
[TBL] [Abstract][Full Text] [Related]
7. The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches.
Lagreca I; Riva G; Nasillo V; Barozzi P; Castelli I; Basso S; Bettelli F; Giusti D; Cuoghi A; Bresciani P; Messerotti A; Gilioli A; Pioli V; Colasante C; Vallerini D; Paolini A; Maccaferri M; Donatelli F; Forghieri F; Morselli M; Colaci E; Leonardi G; Marasca R; Potenza L; Manfredini R; Tagliafico E; Trenti T; Comoli P; Luppi M
Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563634
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.
Hillengass J; Moehler T; Hundemer M
Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683
[TBL] [Abstract][Full Text] [Related]
10. Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability.
Dutta AK; Fink JL; Grady JP; Morgan GJ; Mullighan CG; To LB; Hewett DR; Zannettino ACW
Leukemia; 2019 Feb; 33(2):457-468. PubMed ID: 30046162
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies.
Landgren O
Hematology Am Soc Hematol Educ Program; 2013; 2013():478-87. PubMed ID: 24319222
[TBL] [Abstract][Full Text] [Related]
12. Multiple Myeloma and the Immune Microenvironment.
Kawano Y; Roccaro AM; Ghobrial IM; Azzi J
Curr Cancer Drug Targets; 2017; 17(9):806-818. PubMed ID: 28201978
[TBL] [Abstract][Full Text] [Related]
13. Pathogenesis of myeloma.
Anderson KC; Carrasco RD
Annu Rev Pathol; 2011; 6():249-74. PubMed ID: 21261519
[TBL] [Abstract][Full Text] [Related]
14. Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma.
Paiva B; Pérez-Andrés M; Vídriales MB; Almeida J; de las Heras N; Mateos MV; López-Corral L; Gutiérrez NC; Blanco J; Oriol A; Hernández MT; de Arriba F; de Coca AG; Terol MJ; de la Rubia J; González Y; Martín A; Sureda A; Schmidt-Hieber M; Schmitz A; Johnsen HE; Lahuerta JJ; Bladé J; San-Miguel JF; Orfao A; ;
Leukemia; 2011 Apr; 25(4):697-706. PubMed ID: 21252988
[TBL] [Abstract][Full Text] [Related]
15. Clonal Evolution of Multiple Myeloma-Clinical and Diagnostic Implications.
Salomon-Perzyński A; Jamroziak K; Głodkowska-Mrówka E
Diagnostics (Basel); 2021 Aug; 11(9):. PubMed ID: 34573876
[TBL] [Abstract][Full Text] [Related]
16. MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology.
Mateos MV; Landgren O
Cancer Treat Res; 2016; 169():3-12. PubMed ID: 27696254
[TBL] [Abstract][Full Text] [Related]
17. The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells.
López-Corral L; Gutiérrez NC; Vidriales MB; Mateos MV; Rasillo A; García-Sanz R; Paiva B; San Miguel JF
Clin Cancer Res; 2011 Apr; 17(7):1692-700. PubMed ID: 21325290
[TBL] [Abstract][Full Text] [Related]
18. Multiple Myeloma: Molecular Pathogenesis and Disease Evolution.
Heider M; Nickel K; Högner M; Bassermann F
Oncol Res Treat; 2021; 44(12):672-681. PubMed ID: 34749378
[TBL] [Abstract][Full Text] [Related]
19. Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma.
Manier S; Kawano Y; Bianchi G; Roccaro AM; Ghobrial IM
Curr Opin Hematol; 2016 Jul; 23(4):426-33. PubMed ID: 27101529
[TBL] [Abstract][Full Text] [Related]
20. Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma.
Salem DA; Korde N; Venzon DJ; Liewehr DJ; Maric I; Calvo KR; Braylan R; Tembhare PR; Yuan CM; Landgren CO; Stetler-Stevenson M
Leuk Lymphoma; 2018 Jan; 59(1):178-186. PubMed ID: 28540748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
